200 related articles for article (PubMed ID: 7981772)
21. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Bruynzeel AM; Mul PP; Berkhof J; Bast A; Niessen HW; van der Vijgh WJ
Cancer Chemother Pharmacol; 2006 Nov; 58(5):699-702. PubMed ID: 16565833
[TBL] [Abstract][Full Text] [Related]
22. Acute exercise protects against doxorubicin cardiotoxicity.
Wonders KY; Hydock DS; Schneider CM; Hayward R
Integr Cancer Ther; 2008 Sep; 7(3):147-54. PubMed ID: 18815146
[TBL] [Abstract][Full Text] [Related]
23. Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration.
Gabizon A; Meshorer A; Barenholz Y
J Natl Cancer Inst; 1986 Aug; 77(2):459-69. PubMed ID: 3461207
[TBL] [Abstract][Full Text] [Related]
24. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart.
Sun X; Zhou Z; Kang YJ
Cancer Res; 2001 Apr; 61(8):3382-7. PubMed ID: 11309296
[TBL] [Abstract][Full Text] [Related]
25. Antioxidant enzymes activity and lipid peroxidation in liver and kidney of rats exposed to cadmium and ethanol.
Jurczuk M; Brzóska MM; Moniuszko-Jakoniuk J; Gałazyn-Sidorczuk M; Kulikowska-Karpińska E
Food Chem Toxicol; 2004 Mar; 42(3):429-38. PubMed ID: 14871584
[TBL] [Abstract][Full Text] [Related]
26. Time-course of lipid peroxidation in different organs of mice treated with Echis pyramidum snake venom.
Al Asmari A; Al Moutaery K; Manthari RA; Khan HA
J Biochem Mol Toxicol; 2006; 20(2):93-5. PubMed ID: 16615057
[TBL] [Abstract][Full Text] [Related]
27. Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs.
Imondi AR; Della Torre P; Mazué G; Sullivan TM; Robbins TL; Hagerman LM; Podestà A; Pinciroli G
Cancer Res; 1996 Sep; 56(18):4200-4. PubMed ID: 8797592
[TBL] [Abstract][Full Text] [Related]
28. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of buthionine sulfoximine-enhanced doxorubicin toxicity in metallothionein overexpressing transgenic mouse heart.
Wu HY; Kang YJ
J Pharmacol Exp Ther; 1998 Nov; 287(2):515-20. PubMed ID: 9808675
[TBL] [Abstract][Full Text] [Related]
30. [Effect of biological membrane stabilizing drugs (coenzyme Q10, dextran sulfate and reduced glutathione) on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice].
Shinozawa S; Kawasaki H; Gomita Y
Gan To Kagaku Ryoho; 1996 Jan; 23(1):93-8. PubMed ID: 8546477
[TBL] [Abstract][Full Text] [Related]
31. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice.
Nozaki N; Shishido T; Takeishi Y; Kubota I
Circulation; 2004 Nov; 110(18):2869-74. PubMed ID: 15505089
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity.
Bai P; Mabley JG; Liaudet L; Virág L; Szabó C; Pacher P
Oncol Rep; 2004 Feb; 11(2):505-8. PubMed ID: 14719091
[TBL] [Abstract][Full Text] [Related]
33. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes.
Huang SK; Stauffer PR; Hong K; Guo JW; Phillips TL; Huang A; Papahadjopoulos D
Cancer Res; 1994 Apr; 54(8):2186-91. PubMed ID: 8174126
[TBL] [Abstract][Full Text] [Related]
34. Early postburn lipid peroxidation: effect of ibuprofen and allopurinol.
Demling RH; LaLonde C
Surgery; 1990 Jan; 107(1):85-93. PubMed ID: 2296760
[TBL] [Abstract][Full Text] [Related]
35. Dynamics of lipid peroxidation in isoprenaline-induced myocardiopathy.
Uzunova P; Sokolova TZ; Galabova T; Peneva V; Taskov M; Ribarov S
Cor Vasa; 1991; 33(4):333-42. PubMed ID: 1743029
[TBL] [Abstract][Full Text] [Related]
36. New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity.
El-Demerdash E; Ali AA; Sayed-Ahmed MM; Osman AM
Cancer Chemother Pharmacol; 2003 Nov; 52(5):411-6. PubMed ID: 12879278
[TBL] [Abstract][Full Text] [Related]
37. A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study.
Kogan NM; Schlesinger M; Peters M; Marincheva G; Beeri R; Mechoulam R
J Pharmacol Exp Ther; 2007 Aug; 322(2):646-53. PubMed ID: 17478614
[TBL] [Abstract][Full Text] [Related]
38. Inhibitory effect of dioxopiperazine compounds on malondialdehyde formation induced by doxorubicin in rat liver mitochondria in vitro.
Zhang Y; Hua HY; Zhang TM
Zhongguo Yao Li Xue Bao; 1993 Jul; 14(4):340-3. PubMed ID: 8249630
[TBL] [Abstract][Full Text] [Related]
39. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice.
Forrest GL; Gonzalez B; Tseng W; Li X; Mann J
Cancer Res; 2000 Sep; 60(18):5158-64. PubMed ID: 11016643
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Alderton PM; Gross J; Green MD
Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
